Hot Topics in Diabetes and Endocrinology for Primary Care 2017, December 2, 2017

Anderson, CA US
December 2, 2017

Welcome, and thank you for attending the California Chapter of the American Association of Clinical Endocrinologists: Hot Topics in Diabetes and Endocrinology for Primary Care Program

The California Chapter of AACE program committee has worked very hard to provide a relevant activity for the practicing clinical physician and other healthcare providers seeking education with an emphasis in endocrine disease.

This program has been planned to provide pertinent scientific and clinical information to help you achieve the best solutions in the diagnosis and therapeutic management of patients presenting with endocrine disease. Attendees will obtain updates in not only common and uncommon endocrine disorders, but also newer treatment modalities.

Providing exceptional patient care requires continuing high quality education. The American Association of Clinical Endocrinologists (AACE) was founded in 1991 by a visionary group of leaders to serve as the active voice for clinical endocrinologists. The impetus behind AACE's efforts has always been quality and cost-effective patient care for those with endocrine diseases and disorders. We hope that you will find this program of great value to you in your practice.

Target Audience

Family Practice, Internal Medicine Physicians, Nurse Practitioners, Physician Assistants and other health care professionals interested in the treatment of diabetes and other common endocrine diseases living in and around Redding, CA.

Learning Objectives

  1. After participating in a pre-meeting assessment tool, attendees will be able to recognize areas of potential shortcoming and strive to improve knowledge and consequential healthcare practices.
  2. How to implement the 2017 AACE Diabetes Algorithm into your practice (and make your life easier and patients happier!)
  3. Utilize opportunities to meet and exceed quality indicators for T2DM Treatment: Evaluating options with focus on incorporating:
    • Incretin Rx (DPP4's and GLP-1) Therapy
    • SGLT2 Inhibitors-Potential and Pitfalls
  4. Discuss current DM medications that improve CV risk independent of glucose lowering
  5. Recognize when advanced Beta Cell failure is present and basal insulin is necessary
  6. Know when the newer basal insulin formulations are indicated and how to use these with other agents such as GLP-1 agonists
  7. Incorporate the newest methods to collect and interpret blood glucose data in your practice
  8. Identify key components in evaluating the ambulatory glucose profile in order to minimize glucose variability and hypoglycemia of patients with diabetes
  9. Understand why we have to move beyond LDL-C alone to lower risk further
  10. Introduce the New AACE Lipid Guidelines
  11. Incorporate new agents to lower LDL cholesterol into a treatment paradigm
  12. Be able to recommend optimal dietary regimens for patients with diabetes and cardiovascular risk factors.
  13. How to communicate to your patients about obesity and its associated health consequences and co-morbidities while acknowledging their main motivations
  14. Utilize the newest pharmacologic agents approved for use in obese patients
  15. Navigating billing procedures and insurance coverage (or lack thereof) for weight management in appropriate patients
  16. Enable Primary Care to be at the forefront of Fracture Risk Assessment and Osteoporosis Diagnosis
  17. Be able to undertake a Workup for Evaluating Secondary Causes of Osteoporosis and know when to refer out.
  18. Utilize Appropriate Treatment Modalities in Management of Patients with Osteoporosis
  19. Describe Non-Pharmacological Strategies for Fracture Prevention in Patients with Osteoporosis
  20. At the conclusion of the meeting, attendees will be able to measure learning that occurred that will enable the use of new healthcare techniques and practices and to review or confirm existing care modalities.
Additional information
Available for MOC Points?: 
No
Practice Area: 
Diabetes
Hypoglycemia
Obesity
General Endo
Course summary
Available credit: 
  • 4.50 AMA
  • 4.50 Attendance
Course opens: 
12/02/2017
Course expires: 
12/02/2018
Event starts: 
12/02/2017 - 7:00am
Event ends: 
12/02/2017 - 12:45pm
Cost:
$0.00

Program Agenda

* Please click on the speaker’s name to view each presentation.

Saturday, December 2, 2017

7:00 – 7:50 AMBreakfast / Registration
7:50 – 8:10 AMWelcome & Pre Meeting Assessment

Objectives

  1. After participating in a pre-meeting assessment tool, attendees will be able to recognize areas of potential shortcoming and strive to improve knowledge and consequential healthcare practices.
8:10 – 9:00 AMNew Advances in Pharmacotherapy in Management of Patients with Type 2 Diabetes 
Karen Earle, MD

Objectives

  1. How to implement the 2017 AACE Diabetes Algorithm into your practice (and make your life easier and patients happier!)
  2. Utilize opportunities to meet and exceed quality indicators for T2DM Treatment: Evaluating options with focus on incorporating:
    • Incretin Rx (DPP4's and GLP-1) Therapy
    • SGLT2 Inhibitors-Potential and Pitfalls
  3. Discuss current DM medications that improve CV risk independent of glucose lowering
9:00 – 10:00 AMUtilizing Current and Novel Basal Insulin Formulations in Practice, and, How to Incorporate Ambulatory Glucose Profile to Go Beyond A1C and Reduce Variability and Hypoglycemia 
Etie Moghissi, MD, FACP, FACE

Objectives

  1. Recognize when advanced Beta Cell failure is present and basal insulin is necessary
  2. Know when the newer basal insulin formulations are indicated and how to use these with other agents such as GLP-1 agonists
  3. Incorporate the newest methods to collect and interpret blood glucose data in your practice
  4. Identify key components in evaluating the ambulatory glucose profile in order to minimize glucose variability and hypoglycemia of patients with diabetes
10:00 – 10:30 AMBreak
10:30 – 11:00 AMNew Approaches to Cardiovascular Risk Management 
Chris Guerin, MD, FNLA, FACE

Objectives

  1. Understand why we have to move beyond LDL-C alone to lower risk further
  2. Introduce the New AACE Lipid Guidelines
  3. Incorporate new agents to lower LDL cholesterol into a treatment paradigm
  4. Be able to recommend optimal dietary regimens for patients with diabetes and cardiovascular risk factors.
11:00 – 11:10 AMQ & A
11:10 – 11:40 AMSuccessful Obesity Management and Counseling 
William Zigrang, MD, CCD, FACE

Objectives

  1. How to communicate to your patients about obesity and its associated health consequences and co-morbidities while acknowledging their main motivations
  2. Utilize the newest pharmacologic agents approved for use in obese patients
  3. Navigating billing procedures and insurance coverage (or lack thereof) for weight management in appropriate patients
11:40 – 11:50 AMQ & A
11:50 – 12:20 PMNew Advances in Management of Osteoporosis 
David Chappell, MD

Objectives

  1. Enable Primary Care to be at the forefront of Fracture Risk Assessment and Osteoporosis Diagnosis
  2. Be able to undertake a Workup for Evaluating Secondary Causes of Osteoporosis and know when to refer out.
  3. Utilize Appropriate Treatment Modalities in Management of Patients with Osteoporosis
  4. Describe Non-Pharmacological Strategies for Fracture Prevention in Patients with Osteoporosis
12:20 – 12:30 PMQ & A
12:30 – 12:45 PMPost Meeting Assessment 

Objectives

  1. At the conclusion of the meeting, attendees will be able to measure learning that occurred that will enable the use of new healthcare techniques and practices and to review or confirm existing care modalities.
12:45 PMAdjourn
Gaia Hotel
4125 Riverside Place
Anderson, CA 96007
United States

David Chappell, MD
Private Practice
Petaluma, CA

Karen Earle, MD
Chief of Endocrinology, California Pacific
Medical Center Medical Director, Center for Diabetes Services, CPMC
Assistant Program Director, Endocrinology Fellowship, CPMC
Division Chief, Medical and Surgical Subspecialties, Sutter West Bay Medical Foundation
San Francisco, CA

*Chris Guerin, MD, FACE, FNLA
Assistant Clinical Professor of Medicine
University of California
Oceanside, CA

*Etie Moghissi, MD, FACP, FACE
Clinical Associate Professor
University of California Los Angeles
Marina Del Rey, CA

William D. Zigrang, MD, CCD, FACE
Board of Directors, AACE
Past President, California Chapter of AACE
Mills-Peninsula Health Systems
Burlingame, CA

*Indicates both a member of the Program Committee and faculty.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Association of Clinical Endocrinologists (AACE) and the California Chapter of AACE. The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association of Clinical Endocrinologists (AACE) designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 4.50 AMA
  • 4.50 Attendance

Accreditation Period

Course opens: 
12/02/2017
Course expires: 
12/02/2018

Price

Cost:
$0.00
Please login or register to take this course.